Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 328 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Alzheimer's Disease (AD) Clear all
Completed Phase 2 Interventional Results available

Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)

NCT00857506
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • Costa Mesa, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2013 · Synced Jun 10, 2026, 5:06 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

NCT03114657
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Crenezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
48
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Jun 10, 2026, 5:06 AM EDT
Completed Phase 2 Interventional

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

NCT00151333
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SRA-333
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
3
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2009 · Synced Jun 10, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability

NCT02002819
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
levetiracetam
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Jun 10, 2026, 5:06 AM EDT
Recruiting Not applicable Interventional

Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease

NCT05795634
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Trier Social Stress Test
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jun 10, 2026, 5:06 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study

NCT07146412
View directory record Official record
Conditions
Cognitive Impairment, Alzheimer Blood Biomarkers, Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Interventions
Multimodal Lifestyle Intervention
Behavioral
Lead sponsor
HudsonAlpha Institute for Biotechnology
Other
Eligibility
65 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Jun 10, 2026, 5:06 AM EDT
Terminated Phase 2 Interventional Results available

Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease

NCT02503501
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease (AD)
Interventions
Insulin glulisine, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Jun 10, 2026, 5:06 AM EDT
Not yet recruiting Phase 2 Interventional

A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

NCT07636811
View directory record Official record
Conditions
Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Interventions
Mivelsiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
40 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Maitland, Florida • Naples, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 10, 2026, 5:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tools for Distance Delivery of an Evidence-based AD Family Caregiver Intervention

NCT02347202
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Online counseling via Zoom teleconferencing, Telephone support as needed
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 125 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Jun 10, 2026, 5:06 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

NCT01689233
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
TRx0237 200 mg/day, Placebo
Drug
Lead sponsor
TauRx Therapeutics Ltd
Industry
Eligibility
Up to 89 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
58
States / cities
Phoenix, Arizona • Bellflower, California • Costa Mesa, California + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Jun 10, 2026, 5:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bilateral Brain Dynamics in Cognition and Aging

NCT03224988
View directory record Official record
Conditions
Alzheimer Disease, Aging, MCI
Interventions
TMS
Device
Lead sponsor
Duke University
Other
Eligibility
60 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Jun 10, 2026, 5:06 AM EDT
Terminated Phase 2 Interventional Results available

A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

NCT04798989
View directory record Official record
Conditions
Alzheimer's Disease With Vascular Pathology
Interventions
CY6463, Placebo
Drug
Lead sponsor
Tisento Therapeutics
Industry
Eligibility
60 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Scottsdale, Arizona • Miami, Florida • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Jun 10, 2026, 5:06 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease

NCT02547818
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ALZT-OP1a, ALZT-OP1b, Placebo ALZT-OP1a, Placebo ALZT-OP1b
Drug · Other
Lead sponsor
AZTherapies, Inc.
Industry
Eligibility
55 Years to 79 Years
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
69
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Jun 10, 2026, 5:06 AM EDT
Completed Phase 2 Interventional

A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

NCT04867616
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Bepranemab
Other · Biological
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
50 Years to 80 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
40
States / cities
Fresno, California • Fullerton, California • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Jun 10, 2026, 5:06 AM EDT
Completed Not applicable Interventional

Deep Brain Stimulation with LIFUP for Mild Cognitive Impairment and Mild Alzheimer's Disease

NCT03347084
View directory record Official record
Conditions
Brain Imaging, Mild Cognitive Impairment, Alzheimer Disease, Deep Brain Stimulation
Interventions
Excitation, Inhibition
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
55 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Jun 10, 2026, 5:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD

NCT03389698
View directory record Official record
Conditions
Alzheimer Disease
Interventions
GRASP Dynamic Contrast-Enhanced (DCE) MRI, 3T Brain Scan, Gadolinium-based Contrast Agent (GBCA) for MRI
Device · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
20 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Jun 10, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

Prazosin for Agitation in Alzheimer's Disease

NCT03710642
View directory record Official record
Conditions
Alzheimer's Disease, Disruptive Behavior
Interventions
Prazosin, Placebo oral capsule
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Sun City, Arizona • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Jun 10, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

Raloxifene for Women With Alzheimer's Disease

NCT00368459
View directory record Official record
Conditions
Alzheimer Disease
Interventions
raloxifene, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
60 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
4
States / cities
Santa Rosa, California • Stanford, California • Springfield, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Jun 10, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

NCT04566003
View directory record Official record
Conditions
Alzheimer Disease (AD)
Interventions
[18F]GTP1, [18F]PI-2620, [18F]MK-6240
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Jun 10, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

Nasal Protollin in Early Symptomatic Alzheimer's Disease

NCT07187141
View directory record Official record
Conditions
Alzheimer Disease (AD)
Interventions
Protollin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jun 10, 2026, 5:06 AM EDT
Active, not recruiting Not applicable Interventional

Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure

NCT05584241
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Amnestic Mild Cognitive Disorder
Interventions
Diagnostic Disclosure Protocol, Biomarker Disclosure Protocol
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jun 10, 2026, 5:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

NCT03545789
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease, Progressive Supranuclear Palsy
Interventions
[18F]MNI-958
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jun 10, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

Memesto Wearable Device for Persons With Dementia

NCT05153161
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Memesto
Device
Lead sponsor
Edgewater Safety Systems, Inc.
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Jun 10, 2026, 5:06 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Epidemiology and Biomarker Study in Alzheimer's Disease

NCT07142954
View directory record Official record
Conditions
Alzheimer Disease
Interventions
P-tau217 Test
Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 75 Years
Enrollment
3,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 10, 2026, 5:06 AM EDT